Short answer
Sight Sciences, Inc. (SGHT) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $20M (down 1.2% year over year) with net income of −$8M.
Q3 2025 key financials · XBRL
- Revenue
- $20M
- −1.2% YoY · +1.7% QoQ
- Net income
- −$8M
- +26.2% YoY · +31.6% QoQ
- Operating margin
- -39.7%
- Gross margin
- 86.4%
- EPS (diluted)
- −$0.15
- +28.6% YoY · +34.8% QoQ
Source: XBRL data from the Sight Sciences, Inc. (SGHT) Q3 2025 10-Q on SEC EDGAR. USD.
Sight Sciences, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No Risk Factors section provided; supplied text contains only forward-looking-statement disclosures
- No newly added risk or material update identifiable from the provided excerpt
- Reimbursement risk: Surgical Glaucoma reimbursement protection and Dry Eye reimbursement expansion remain key uncertainties
- Regulatory risk: Extensive government regulation may affect products, operations, and compliance
- Financial risk: Secured credit facility compliance and favorable payment terms remain uncertain
- Market risk: Competition from existing competitors and new entrants may limit growth
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Sight Sciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.